Stock comparison
Mettler-Toledo International
Rigel Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | RIGL | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 47D | MTD |
| Benjamin Graham | 65B | 34F | MTD |
| Philip Fisher | 63C | 54C | MTD |
| Peter Lynch | 66B | 54C | MTD |
| Joel Greenblatt | 68B | 48D | MTD |
| Charlie Munger | 74B | 62D | MTD |
| Terry Smith | 70B | 61C | MTD |
Side-by-side metrics
| Metric | MTD | RIGL |
|---|---|---|
| Market cap | $22.29B | $536.75M |
| P/E (TTM) | 25.3x | 1.4x |
| EV/EBIT | 21.6x | 4.3x |
| ROIC (TTM) | 36.09% | 27.96% |
| Gross margin | 57.79% | 93.39% |
| Net margin | 21.4% | 121.51% |
| Revenue CAGR 5y | 2.01% | 18.5% |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 0.1x+100%
- Market cap$22.29Bvs $536.75M+98%
- ROIC (TTM)36.09%vs 27.96%+23%
RIGL leads on
- P/E (TTM)1.4xvs 25.3x+94%
- Revenue CAGR 5y18.5%vs 2.01%+89%
- Net margin121.51%vs 21.4%+82%
- EV/EBIT4.3xvs 21.6x+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.